One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia

Tomsk National Research Medical Center of the Russian Academy of Sciences380 enrolled

Overview

The primary objective of the study is to assess the cardiac status of COVID-19 pneumonia patients during 1 year after discharge

Although COVID-19 manifests in most cases with respiratory symptoms, cardiovascular abnormalities is common in hospitalized patients. Patients with cardiovascular risk factors or established disease appear to have a worse prognosis. Myocardial dysfunction could be a direct manifestation of COVID-19. The investigators hypothesize that subjects after COVID-19 pneumonia present myocardial and vascular remodeling during 1 year after discharge, even in the absence of prior cardiovascular disease.

Study Type

OBSERVATIONAL

Enrollment

380

Conditions

Covid19 Cardiac Complication

Interventions

Evaluation of clinical, instrumental and laboratory diagnostics testsDIAGNOSTIC_TEST

During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: -Patients with documented COVID-19 pneumonia Exclusion Criteria: * Patients with cancer * Impossible to follow up

Locations (1)

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

Tyumen, Russia

Outcomes

Primary Outcomes

Echocardiographic assessment of cardiac function

Echocardiographic assessment of global strain parameters at 3 and 12 months after discharge

Time frame: up to one year

Secondary Outcomes

МАССЕ

Major adverse cardiac and cerebrovascular events: cardiac death, myocardial infarction, or stroke at 3 and 12 months after discharge

Time frame: up to one year

Quantitative analysis of parenchymal lung damage

Describe the parenchymal lung damage through a quantitative analysis with chest CT at 3 and 12 months after discharge

Time frame: up to one year

Functional exercises capacity assessment

Six-min walk test at 3 and 12 months after discharge

Time frame: up to one year

Evaluation of renal function

Measure of creatinine clearance at 3 and 12 months after discharge

Time frame: up to one year

Evaluation of inflammation

Analysis for C-reactive protein at 3 and 12 months after discharge

Time frame: up to one year

Evaluation of coagulation abnormality

Analysis for activated clotting time at 3 and 12 months

Time frame: up to one year

Evaluation of quality of life in first year after discharge

Assessment of the Short Form Health Survey (SF36) at 3 and 12 months after discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.